MYC and neoplasm: For example, in Case #39, the clonal prevalence of the subclone labelled G, containing mutations in FGFR1, KMT2D, MYC driver genes, was ~0.27 in the pre-treatment tumour biopsy, decreased to ~0.22 in post cycle 1 treatment tumour biopsy but increased to ~0.34 in the lymph node biopsy (Fig. 7c).